What type of study is this?

This is a Literature Review study.

September 12, 2025International Journal of Innovative Technologies in Social ScienceOpen Access

Luspatercept – An Innovative Approach to the Treatment of Anemia in Beta-Thalassemia and Myelodysplastic Syndromes

View Full Paper

Ask AI

Bookmark

Authors

DDDominik DomońMedical University of Warsaw ANAdam NiedzielaMedical University of Warsaw HWHanna WilskaMedical University of Warsaw

Discussion

Member takes

Implication

This review highlights luspatercept’s efficacy in reducing anemia in beta-thalassemia and myelodysplastic syndromes, suggesting a new treatment approach.

Key Points

Luspatercept significantly reduces transfusion burden in patients with beta-thalassemia, enhancing treatment outcomes.
The BELIEVE trial revealed a ≥33% transfusion reduction in a higher proportion of patients treated with luspatercept compared to placebo.
In low-risk MDS, luspatercept promotes erythroid response and transfusion independence, indicating its potential broad applicability.
Ongoing research will further clarify luspatercept's role across diverse patient populations, supporting its place in clinical practice.

Cite This Study

Domoń et al. (2025) studied this question.

synapsesocial.com/papers/68d46cc631b076d99fa68df7 https://doi.org/10.31435/ijitss.3(47).2025.3597

View Full Paper

Ask AI

Bookmark

September 12, 2025International Journal of Innovative Technologies in Social ScienceOpen Access

Luspatercept – An Innovative Approach to the Treatment of Anemia in Beta-Thalassemia and Myelodysplastic Syndromes

View Full Paper

Ask AI

Bookmark

Authors

DDDominik DomońMedical University of Warsaw ANAdam NiedzielaMedical University of Warsaw HWHanna WilskaMedical University of Warsaw

Discussion

Member takes

Implication

This review highlights luspatercept’s efficacy in reducing anemia in beta-thalassemia and myelodysplastic syndromes, suggesting a new treatment approach.

Key Points

Luspatercept significantly reduces transfusion burden in patients with beta-thalassemia, enhancing treatment outcomes.
The BELIEVE trial revealed a ≥33% transfusion reduction in a higher proportion of patients treated with luspatercept compared to placebo.
In low-risk MDS, luspatercept promotes erythroid response and transfusion independence, indicating its potential broad applicability.
Ongoing research will further clarify luspatercept's role across diverse patient populations, supporting its place in clinical practice.

Cite This Study

Domoń et al. (2025) studied this question.

synapsesocial.com/papers/68d46cc631b076d99fa68df7 https://doi.org/10.31435/ijitss.3(47).2025.3597

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark